Lupin launches Betamethasone Dipropionate Ointment USP (Augmented)

Lupin announced the launch of Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, having received an approval from the United Stat es Food and Drug Admini stration (U.S. FDA) earli er. The product would be manufactured at Lupin's Pithampur (Unit Ill) facility, India.

Betamethasone Dipropionate Ointment USP (Augmented), 0 .05%, is the generic equivalent of Diprolene Ointment, 0.05%, of Merck Sharp and Dohme Corp. It is a corticosteroid indicated for t he relief of the inflammatory and pruritic manifestations of cort icosteroid -responsive dermatoses in patients 13 years of age and older.

Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, (RLD: Diprolene) had an annual sales of approximately USD 21 million in t he U.S. (IQVIA MAT Jan uary 2020).

 

Powered by Capital Market - Live News